{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:41:05Z","timestamp":1760812865250,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.trim.2022.101733","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T19:54:42Z","timestamp":1667678082000},"page":"101733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Outcomes after anti-thymocyte globulin vs Basiliximab induction before deceased donor kidney transplants"],"prefix":"10.1016","volume":"75","author":[{"given":"Muhammad Saad","family":"Hafeez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneeb Ul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Shahyan","family":"Bakhthiyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumael","family":"Azhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Arslan Yousuf","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhamidipati V.","family":"Ramana Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.trim.2022.101733_bb0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamasurg.2014.2038","article-title":"Survival benefit of solid-organ transplant in the United States","volume":"150","author":"Rana","year":"2015","journal-title":"JAMA Surg."},{"author":"Organ Donation and Transplantation Statistics","key":"10.1016\/j.trim.2022.101733_bb0015"},{"author":"Annual Data Report","key":"10.1016\/j.trim.2022.101733_bb0020"},{"issue":"7","key":"10.1016\/j.trim.2022.101733_bb0025","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/tri.12043","article-title":"Selection of induction therapy in kidney transplantation","volume":"26","author":"Hardinger","year":"2013","journal-title":"Transpl. Int."},{"issue":"4","key":"10.1016\/j.trim.2022.101733_bb0030","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.transproceed.2018.01.022","article-title":"Efficacy and safety of induction therapy in kidney transplantation: a network Meta-analysis","volume":"50","author":"Hwang","year":"2018","journal-title":"Transplant. Proc."},{"issue":"5","key":"10.1016\/j.trim.2022.101733_bb0035","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/AOG.0000000000002918","article-title":"Incidence of venous thromboembolism after different modes of gynecologic surgery","volume":"132","author":"Jorgensen","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.trim.2022.101733_bb0040","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.transproceed.2020.08.025","article-title":"Opportunistic infections after induction with Alemtuzumab or Basiliximab: a 3-year kidney transplantation experience","volume":"53","author":"Florescu","year":"2021","journal-title":"Transplant. Proc."},{"issue":"3","key":"10.1016\/j.trim.2022.101733_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2146\/ajhp090636","article-title":"Induction immunosuppressive therapies in renal transplantation","volume":"68","author":"Gabardi","year":"2011","journal-title":"Am. J. Health Syst. Pharm."},{"article-title":"Profiling risk for acute rejection in kidney transplantation: recipient age is a robust risk factor","year":"2022","series-title":"Semantic Scholar","key":"10.1016\/j.trim.2022.101733_bb0050"},{"issue":"8","key":"10.1016\/j.trim.2022.101733_bb0055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1517\/14656566.2013.788151","article-title":"Current pharmacotherapeutical options for the prevention of kidney transplant rejection","volume":"14","author":"Schaefer","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.trim.2022.101733_bb0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ajt.13884","article-title":"Induction therapy for kidney transplant recipients: do we still need anti-IL2 receptor monoclonal antibodies?","volume":"17","author":"Hellemans","year":"2017","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.trim.2022.101733_bb0065","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1097\/TP.0000000000001577","article-title":"Induction therapy, rejection, and graft outcomes in pediatric and adolescent kidney transplant recipients","volume":"101","author":"Mincham","year":"2017","journal-title":"Transplantation."},{"issue":"12","key":"10.1016\/j.trim.2022.101733_bb0070","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1111\/ajt.16121","article-title":"Kidney transplantation using alemtuzumab, belatacept, and sirolimus: five-year follow-up","volume":"20","author":"Schmitz","year":"2020","journal-title":"Am. J. Transplant."},{"issue":"Suppl. 3","key":"10.1016\/j.trim.2022.101733_bb0075","article-title":"Acute rejection and late renal transplant failure: risk factors and prognosis","volume":"19","author":"Pallard\u00f3 Mateu","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.trim.2022.101733_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2005.00376.x","article-title":"Chronic renal allograft rejection: pathophysiologic considerations","volume":"68","author":"Joosten","year":"2005","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.trim.2022.101733_bb0085","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.transproceed.2013.01.089","article-title":"Does national sharing of kidneys donated after cardiac death lead to poorer outcomes?","volume":"45","author":"Falconer","year":"2013","journal-title":"Transplant. Proc."},{"issue":"15","key":"10.1016\/j.trim.2022.101733_bb0090","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJM200010123431504","article-title":"Twelve years\u2019 experience with national sharing of HLA-matched cadaveric kidneys for transplantation","volume":"343","author":"Takemoto","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.trim.2022.101733_bb0095","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/aor.12473","article-title":"Prognostic significance of 1-year serum albumin levels within the Normal range after kidney transplantation","volume":"39","author":"Oh","year":"2015","journal-title":"Artif. Organs"},{"issue":"8","key":"10.1016\/j.trim.2022.101733_bb0100","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1016\/j.transproceed.2019.02.061","article-title":"Effectiveness of thymoglobulin induction therapy in kidney transplant from deceased donor with mild to moderate acute kidney injury","volume":"51","author":"Lee","year":"2019","journal-title":"Transplant. Proc."},{"issue":"4","key":"10.1016\/j.trim.2022.101733_bb0105","doi-asserted-by":"crossref","first-page":"310","DOI":"10.6002\/ect.2012.0103","article-title":"Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function","volume":"11","author":"Chen","year":"2013","journal-title":"Exp. Clin. Transplant."},{"issue":"3","key":"10.1016\/j.trim.2022.101733_bb0110","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.transproceed.2020.01.054","article-title":"Low-dose thymoglobulin vs Basiliximab induction therapy in low-risk living related kidney transplant recipients: a prospective randomized trial","volume":"53","author":"Martinez-Mier","year":"2021","journal-title":"Transplant. Proc."},{"issue":"11","key":"10.1016\/j.trim.2022.101733_bb0115","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200969110-00007","article-title":"Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection","volume":"69","author":"Deeks","year":"2009","journal-title":"Drugs."},{"issue":"5","key":"10.1016\/j.trim.2022.101733_bb0120","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/infdis\/jiz194","article-title":"Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs","volume":"220","author":"Kaminski","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.trim.2022.101733_bb0125","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11255-020-02418-w","article-title":"Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis","volume":"52","author":"Ali","year":"2020","journal-title":"Int. Urol. Nephrol."},{"issue":"7","key":"10.1016\/j.trim.2022.101733_bb0130","article-title":"The risk of Postkidney transplant outcomes by induction choice differs by recipient age","volume":"7","author":"Ahn","year":"2021","journal-title":"Transplant Direct."},{"issue":"19","key":"10.1016\/j.trim.2022.101733_bb0135","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N. Engl. J. Med."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:04:04Z","timestamp":1760810644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422002076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"alternative-id":["S0966327422002076"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101733","relation":{},"ISSN":["0966-3274"],"issn-type":[{"type":"print","value":"0966-3274"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes after anti-thymocyte globulin vs Basiliximab induction before deceased donor kidney transplants","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101733"}}